

# Appendix 3Y

## Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity</b>	<b>OSPREY MEDICAL INC.</b>
<b>ABN</b>	<b>ARBN 152 854 923</b>

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Sandra Lesenfants
<b>Date of last notice</b>	15 May 2019

### Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Direct	
<b>Nature of indirect interest (including registered holder)</b> <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	N/A	
<b>Date of change</b>	8 January 2021	
<b>No. of securities held prior to change</b>	211,833	Options (OSPAO) with exercise price of A\$0.38 per Share
	40,000	Options (OSPAO) with exercise price of A\$0.26 per Share
	Total: <u>251,833</u> Options (OSPAO) (exercisable into an equivalent of 503,666 CDIs)	
<b>Class issued</b>	Options over Shares (not quoted)	
<b>No. of securities issued</b>	331,713 Options (OSPAO) (exercisable into an equivalent of 663,426 CDIs)	

+ See chapter 19 for defined terms.

## Appendix 3Y

## Change of Director's Interest Notice

<b>Value/Consideration</b>	In accordance with Osprey’s cost reduction initiatives introduced in early 2020 and the Option terms approved by stockholders on 19 June 2020, unlisted Options have been granted to Ms Lesenfants in lieu of directors’ fees of US\$11,250 for the period 1 October 2020 to 31 December 2020. The calculation for the number of Options issued was based upon the closing price of the Company’s CDIs trading on ASX on 31 December 2020.
<b>Note:</b> If consideration is non-cash, provide details and estimated valuation	
<b>Number disposed/cancelled</b>	Nil
<b>No. of securities held after change</b>	<div>211,833 Options (OSPAO) with exercise price of A\$0.38 per Share</div> <div>40,000 Options (OSPAO) with exercise price of A\$0.26 per Share</div> <div>331,713 Options (OSPAO) with exercise price of A\$0.05 per Share</div>
	Total: 583,546 Options (OSPAO) (exercisable into an equivalent of 1,167,092 CDIs)
<b>Nature of change</b>	Grant of Options pursuant to stockholder approval granted at the Annual Meeting of Stockholders held on 19 June 2020. The exercise price of the Options upon vesting is \$0.05.
Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	

## Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	N/A
<b>Name of registered holder (if issued securities)</b>	N/A
<b>Date of change</b>	N/A

---

+ See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

<b>No. and class of securities to which interest related prior to change</b> <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	N/A
<b>Interest acquired</b>	N/A
<b>Interest disposed</b>	N/A
<b>Value/Consideration</b> <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	N/A
<b>Interest after change</b>	N/A

**Part 3 – +Closed period**

<b>Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?</b>	No
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	N/A
<b>If prior written clearance was provided, on what date was this provided?</b>	N/A

---

+ See chapter 19 for defined terms.